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Khaled Abdel Ghany Baraka aaDepartment of Cardiology, El Minya
a EgyptBackground: Microalbuminuria (MA) is a marker of vascular damage. However, many studies have observed an
increased risk at lower levels of albuminuria than are currently used to define MA.
Aim: To verify early cardiovascular changes occurring before MA in hypertensive patients.
Materials and methods: One hundred and fifty hypertensive patients and 60 normotensive individuals were
divided into normotensive individuals with normal left ventricular (LV) geometry (Group I), hypertensive patients
with normal LV geometry (Group II), and hypertensive patients with abnormal LV geometry (Group III). The LV
mass index, ambulatory arterial stiffness index, flow-mediated dilatation of the brachial artery, and intima-media
thickness (IMT) of the common carotid were assessed. Urinary albumin/creatinine ratio was determined using a
morning spot-urine sample.
Results: Compared with Group I, ambulatory arterial stiffness index and IMT were significantly increased and
flow-mediated dilatation was significantly decreased in Group II; however, MA did not differ between both
groups. These changes were augmented when Group III was compared with Group II. MA significantly
increased in Group III compared with Group II. Receiver operating characteristic analysis revealed that MA,
with a cut-off value of 19.25 mg/g, predicted increased IMT, and abnormal LV geometry in a statistically signif-
icant manner.
Conclusion: Many vascular changes, in the form of increased IMT, reduced vasodilator capacity, and increased
arterial stiffness, preceded MA and any change in LV geometry. The results presented here strengthen the use-
fulness of adopting a lower cut-off to define MA.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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MICROALBUMINURIA IS LATE IN HYPERTENSIONIntroduction
Microalbuminuria (MA) is known to be associ-ated with atherosclerosis and is a strong
independent predictor of an increased risk of car-
diovascular morbidity and mortality independent
of traditional risk factors [1,2]. MA is a well-
known marker of underlying vascular dysfunction
and has been correlated with the structural and
functional integrity of the vasculature [3].
The prevalence of MA is low in the absence of
cardiovascular risk factors and progressively
increases with the number of cardiovascular risk
factors. The main correlate of MA is blood pres-
sure, either systolic or diastolic [4]. The relation-
ship between blood pressure and MA is
continuous and graded because the prevalence
of MA increases with the severity of hypertension
[5].
However, some studies have found that
increased risk is observed at much lower levels
of MA than are currently used to define MA [6].Methods
This study was carried out in the Cardiology
Department at El Minya University Hospital,
Minya, Egypt, over a 13-month period between
December 2013 and January 2015.
This study included 150 newly discovered
untreated hypertensive patients (diagnosed
according to European Society of Hypertension/
European Society of Cardiology guidelines for
management of arterial hypertension) compared
with 60 sex and age matched healthy controls [7].
They were classified into the following three
groups: Group 1: 60 normotensive apparently
healthy individuals with normal (left ventricular)
LV geometry; Group 2: 54 hypertensive patients
with normal LV geometry; and Group 3: 96 hyper-
tensive patients with abnormal LV geometry.
The following exclusion criteria were used in
this study: (1) tobacco smoking; (2) previous
myocardial infarction (3) coronary bypass graft;
(4) cardiac valve disease; (5) stroke; (6) diabetes;
(7) dyslipidaemia; and (8) obesity.
All of the participants (after written consent)
were subjected to the following measurements:
history taking, clinical examination, office blood
pressure measurement (patients with a systolic
blood pressure P140 mmHg and diastolic blood
pressure P90 mmHg were considered to be
hypertensive), body mass index and body surface
area measurements, laboratory investigation (fast-
ing and postprandial blood sugar, lipid profile,
blood urea nitrogen, serum creatinine, glomerularfiltration rate, and quantification of albumin in
urine), and ambulatory blood pressure monitoring
using AMP50 (China).
Calculation of the ambulatory arterial stiffness
index
For each participant, the regression slope of
diastolic on systolic blood pressure was calculated
from 24-hour recordings. The regression line was
not forced through the origin (intercept 0) because
blood pressure does not drop to 0 when the flow
drops to 0 during diastole [8].
The rationale underlying this is that for any
given increase in distending arterial pressure, sys-
tolic and diastolic pressures tend to increase in a
parallel fashion in a compliant artery. By compar-
ison, in a stiff artery, the increase in systolic pres-
sure is accompanied by a lesser increase, or even
by a decrease in diastolic pressure.
The ambulatory arterial stiffness index (AASI)
was defined as 1 minus the regression slope. The
stiffer the arterial tree, the closer the regression
slope and AASI are to 0 and 1, respectively [8].
Assessment of MA
Urinary albumin and creatinine concentrations
were determined using a morning spot-urine
sample. Urine albumin was determined using
the enzyme-linked immunosorbent assay method
[disease related group microalbumin enzyme-
linked immunosorbent assay (EIA-2361) USA],
whereas urinary creatinine was assessed with
the kinetic Jaffe’ method using the Autoanalyzer
Modular (Hitachi–Roche Diagnostics, Man-
neheim, Germany). The urinary albumin-to-
creatinine ratio (ACR) was then calculated. MA
was defined as an ACR of 30–300 mg/g in two pos-
itive tests from three [9].
Colored duplex ultrasound to measure the
intima-media thickness
A carotid ultrasound evaluation was conducted
on all of the participants in this study to determine
the intima-media thickness (IMT) and to detect
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beam 30 UL (Korea) equipped with a liner probe
(7.5 MHz) and a standardized protocol [10].
The individuals were investigated in the supine
position, and the IMT of the far wall was evaluated
as the distance between the luminal–intimal inter-
faces and the medial–adventitial interface approx-
imately 1.5 cm proximal to the carotid bifurcation.
The IMT measurements were obtained from four
contiguous sites at 2-mm intervals, and the
average was calculated. The mean IMT (the mean
of both right and left side) was assessed. Simulta-
neously, the maximum IMT (the highest value
either right or left) was also assessed. The IMT is
considered to be abnormal at levels >0.072 cm [11].
Plaques were defined as focal widenings relative
to adjacent segments with protrusions into the
lumen of calcified or noncalcified material [12].Colored duplex ultrasound to test endothelial
functions
Colored duplex ultrasound was conducted on all
of the participants. The mean right brachial artery
antero–posterior diameter was measured 3–5 cm
above the elbow between the media and adventi-
tia from four cycles synchronized with the end
diastole at the R-wave peaks [13].
A basic scan of the flow was taken. Then, a 2nd
scan was taken after applying a pneumatic tourni-
quet of 250–300 mmHg (using mercurial sphyg-
momanometer) for approximately 4.5 seconds.
The scan was taken 60 seconds after releasing
the tourniquet measuring the maximum flow-





Mean SD Mean SD
Age (y) 45.25 7.88 47.39 8.22
G = group; SD = standard deviation.





Mean SD Mean SD
Office SBP 127.35 5.32 165.56 19.31
Office DBP 77.50 6.39 97.78 10.03
Mean 24 h SBP 123.05 6.65 152.11 22.36
Mean 24 h DBP 74.8 6.63 94.33 10.63
AASI 0.52 .062 0.73 0.10
DBP = diastolic blood pressure; G = group; Mean 24 h DBP = mean 24-hour
pressure; SBP = systolic blood pressure; SD = standard deviation.measured after 15 minutes of rest to allow for the
recovery of the artery after FMD, which was the
basis of the glyceryl trinitrate-mediated dilatation
(GTN-MD) reading. A 4th scan was taken 4 min-
utes after sublingual administration of 400 lg of
GTN spray.
The FMD percentage was calculated using the
following equation:
FMD% ¼ 2
nd Scan 1st scan
1st scan
 100 ð1Þ
The GTN-MD percentage was calculated using
the following equation:
GTN-MD% ¼ 4
th Scan 3rd scan
3rd scan
 100 ð2Þ





Echocardiography evaluation of the LV mass
index (MI) was performed. An evaluation was
conducted according to the following equation:
LV mass ðgÞ ¼ 0:8f1:04½ðLVIDDþ PWTDþ IVSTDÞ3
 ðLVIDDÞ3g þ 0:6 g ð4Þ
where IVSTD = interventricular septum thickness in
diastole; LVIDD = left ventricular internal diameter in
diastole; and PWTD = posterior wall thickness in dias-
tole. LV mass was then indexed to body size by dividing
the raw LV mass by height raised to the power of 2.7.
LV hypertrophy (LVH) was defined as
LVMI > 51 gm/ht2.7 [14]. The geometric pattern
was determined by calculating the relative wall
thickness (RWT) as follows:Group 3
(n = 96)
p
Mean SD G1 vs. G2 G2 vs. G3
48.78 5.19 0.419 0.466




Mean SD G1 vs. G2 G2 vs. G3
170.72 13.68 <0.001 0.276
97.67 11.57 <0.001 0.970
148.59 9.09 <0.001 0.436
92.03 7.1 <0.001 0.364
4 0.79 0.08 <0.001 0.011
diastolic blood pressure; Mean 24 h SBP = mean 24-hour systolic blood
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The following four distinct geometric patterns
were described [14]: normal geometry (normal
LVMI with a RWT < 0.45), concentric remodeling
(normal LVMI with a RWT > 0.45), concentric
hypertrophy (increased LVMI with RWT > 0.45),
and eccentric hypertrophy (increased LVMI asso-
ciated with RWT < 0.45).
Statistical analysis
The data were analyzed using SPSS (SPSS Inc.,
Chicago, Il, USA), version 16 for Windows. All of
the data were reported as the mean ± standard
deviation. Student t test was used to compare
the means of the two groups. The Mann–Whitney
U test was used to compare nonparametric vari-
ables. Differences were considered to be signifi-
cant at a two-tailed p 6 0.05. Receiver-operating
characteristics curve analysis was performed to
assess the accuracy of MA at detecting increased
IMT and LV geometry.Results
As shown in Table 1, the study groups were all
age-matched. There was a statistically significant





Mean SD Mean SD
RCCA-IMT 0.055 0.006 0.083 0.04
LCCA-IMT 0.058 0.011 0.078 0.02
MCCA-IMT 0.058 0.008 0.083 0.03
FMD% 16.08 6.483 10.10 11.01
Dilatation ratio 94.8 40.06 50.28 26.03
FMD% = flow mediated dilatation percent; G = group; LCCA = left common
carotid artery; SD = standard deviation.






Albuminuria (UACR) in mg/g 8.25 2.544 16.65
UACR = urinary albumin creatinine ratio.
Table 5. Receiver operating characteristic analysis for the predictio
Increased IMT (P0.072 cm)
AUC Cut-off value Sensitivity Specificity
MA 0.674 19.25 60 66
AUC = area under the curve; IMT = intima-media thickness; LV = left ventrioffice-based and 24-hour mean systolic and dias-
tolic blood pressures, while there was no signifi-
cant difference between Group 2 and Group 3 in
these parameters. Meanwhile, there were signifi-
cant differences in the AASI between Group 1
and Group 2 and Group 2 and Group 3 (Table 2).
The carotid IMT significantly increased in




Mean SD G1 vs. G2 G2 vs. G3
3 0.089 0.027 0.007 0.535
4 0.109 0.048 0.002 0.013
0 0.102 0.033 0.001 0.047
6.13 4.2 0.046 0.073
54.05 30.4 <0.001 0.660




SD Mean SD G1 vs. G2 G2 vs. G3
21.49 46.74 49.63 0.09 0.019
n of an increased intima-media thickness.
Abnormal LV geometry
AUC Cut-off value Sensitivity Specificity
0.766 19.250 .625 88
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Group 2 (Table 3).
There was a significant decrease in the FMD and
the dilatation ratio in Group 2 compared with
Group 1, while the FMD tended to decrease signif-
icantly in Group 3 compared with Group 2
(Table 3).
However, albuminuria only significantly dif-
fered between Group 2 and Group 3 (i.e., hyper-
tensive patients with and without LVH) because
albuminuria was significantly higher in Group 3
versus Group 2 but not between normotensive
patients (Group 1) and hypertensive patients
without LVH (Group 2; Table 4).
Finally, receiver-operating characteristics analy-
sis revealed that a MA level of 19.25 mg/g accu-
rately and significantly predicted an increased
IMT level (P0.072 cm) and abnormal LV geometry
(Table 5; Figs. 1 and 2).Discussion
MA is a biomarker for chronic kidney disease
and an independent predictor of cardiovascular
and all-cause mortality [15]. Furthermore, MA is
associated with a four-fold increased risk of
ischemic heart disease in patients with untreated
hypertension or borderline hypertension [16].
The main finding from this study was that vas-
cular changes (IMT, FMD, and AASI) significantly
differed between the study groups (lowest in
Group I and highest in Group 3). Similarly, the
blood pressure significantly differed between
these groups (lowest in Group 1 and highest in
Group 3). Thus, vascular changes are assumed toFig. 2. Receiver operating characteristic analysis for the prediction of
abnormal left ventricular geometry.increase during the progression of hypertensive
disease.
However, albuminuria significantly differed
only between Group 2 and Group 3 (i.e., hyperten-
sive patients with and without left ventricular
hypertrophy) but not between normotensive
patients (Group 1) and hypertensive patients
without LVH (Group 2).
Despite the importance of MA as a marker of
high risk, these findings indicate that it is a rela-
tively late LVH event (one area of subclinical tar-
get organ damage); many other sensitive
markers occurred earlier. Therefore, these results
suggest that albuminuria is a late rather than early
marker of end organ damage.
From a pathophysiological point of view, this
finding seems reasonable because MA reflects
vascular (renal) damage; thus, risk might be
increased at very low levels of urine albumin.
These results agree with many other studies
[6,15,17] that have found an increased risk at much
lower levels of albuminuria than currently used to
define MA. Such low levels were shown to predict
heart disease, hypertension, and death, indepen-
dent of age, sex, renal function, diabetes, and
lipids in patients with cardiovascular disease and
hypertension as well as in the general population.
Furthermore, in 2010, Cerasola et al. [18] found
clear evidence that urinary albumin excretion
levels, even below the cut-off values currently
used to diagnose MA, are associated with an
increased risk of cardiovascular events.
Moreover, in a community-based sample of
middle-aged nonhypertensive, nondiabetic indi-
viduals, low levels of urinary albumin excretion
well below the current MA threshold predicted
cardiovascular disease development [19]. These
observations add to the growing body of evidence
that challenges the notion that urine
ACR < 30 mg/g indicates ‘‘normal’’ albumin
excretion [19].
Moreover, results from The Third Copenhagen
City Heart Study have shown that even lower
levels of albuminuria (5 lg/min) are associated
with a worse risk profile and have a strong
independent prognostic value in hypertensive
patients [20].
Similarly, Ratto et al. [21] demonstrated that
lowering the ACR threshold (11.5 mg/g) that is
currently used to detect MA might improve cost-
effectiveness in identifying patients with LVH as
the sensitivity and specificity of this adopted
threshold in identifying patients with LVH was
39% and 92%, respectively [21]. Another study
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MICROALBUMINURIA IS LATE IN HYPERTENSIONassociated with LV dysfunction in the general
population. Thus, the conventional urinary ACR-
threshold of MA (30 mg/g) may be too conserva-
tive given that end-organ damage, such as LVH,
is observed with increased frequency at much
lower levels [22].
This relatively late occurrence of MA in hyper-
tensive patients may be explained by the chal-
lenges of different albumin detection techniques.
The nature of urinary albumin is now known to
be complex. Indeed, albumin is excreted as a mix-
ture of intact albumin (immunoreactive) detected
by routine tests, albumin-derived peptides that
are not detected by routine antibody-based tests,
and a species of intact albumin (immuno-
unreactive albumin), also not detectable with
antibody-based tests [9].
The urine albumin concentration has tradition-
ally been measured with quantitative immuno-
chemical methods, such as immunonephelometry,
immunoturbidimetry, and radioimmunoassay [9].
High performance liquid chromatography tech-
niques used to measure urinary albumin indeed
found some urinary albumin molecules that are
not detected with the standard antibody
techniques.
Moreover, a new test based on high perfor-
mance liquid chromatography identifies the entire
immune-reactive and immuno-unreactive intact
albumin (total intact albumin) in the urine [13].
An underestimation of the total intact urinary
albumin with conventional methods is especially
relevant for a low albumin execration rate
(<20 lg/min by current methods) [9].
Study limitations
Spot urine sampling is subject to both incidental
diurnal variation and the prevalent concentration/
dilution of the urine sample, which over- and
underestimates true albumin excretion, respec-
tively. To overcome this, the urinary albumin/cre-
atinine ratio is used. However, this measurement
is also complicated by the fact that creatinine
excretion varies between sex and within sex.Conclusion
Because albuminuria only significantly differed
between the hypertensive patients with and with-
out LVH, it is tempting to speculate that MA is a
marker of end-organ damage that occurs rela-
tively late in the course of hypertension. MA
showed to be a useful tool in the complex process
of risk stratification revealing a great specificity
and even a lower sensibility. MA might, at least,reflect renal-vascular damage, while FMD, arterial
stiffness, and IMT might be parameters of vascu-
lar stress and/or injury that precede end-organ
damage.
The need to limit costs without compromising
the accuracy of the diagnostic process is rapidly
becoming a major issue for public health. Thus,
we need to devise new, accurate, easy-to-use,
and inexpensive ways to identify patients at risk.
The results presented here strengthen the
usefulness of adopting a lower cut-off to define
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